Advertisement

Influence of Psychotropic Drugs on Pituitary Hormone Secretion with Special Reference to Norepinephrine Reuptake Inhibition

  • G. Laakmann
  • A. Hinz
  • U. Voderholzer
  • R. Lehle
  • H. Neuhauser
  • M. Ortner
  • R. Meissner
Conference paper

Abstract

In the last three decades, pharmacological treatment of psychiatric disorders using neuroleptic drugs, antidepressants, and tranquilizers has become common all over the world. The discovery that antidepressants inhibit the reuptake of norepinephrine (NE) and serotonin (5-HT) and that neuroleptics block the dopamine (DA) receptors led to the NE- and 5-HT-deficiency hypothesis of depression (Schildkraut 1965; Coppen 1967) and the dopamine hypothesis of schizophrenia (Carlsson 1978, 1988). Benzodiazepines are believed to potentiate the GABAergic system (Costa et al. 1978) by binding to specific receptors, called benzodiazepine receptors, which modify the sensitivity of GABA receptors (Squires and Braestrup 1977; Möhler and Okada 1978).

Keywords

Growth Hormone Psychotropic Drug Growth Hormone Secretion Cortisol Secretion Growth Hormone Response 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ajlouni K, el-Khateeb M (1980) Effect of glucose on growth hormone, prolactin and thyroid- stimulating hormone response to diazepam in normal subjects. Horm Res 13: 160–164PubMedCrossRefGoogle Scholar
  2. Balestreri R, Bertolini S, Costello C (1979) The neural regulation of ACTH secretion in man. In: Polleri A, MacLeod RM (eds) Neuroendocrinology: biological and clinical aspects. Academic, London, pp 155–185Google Scholar
  3. Beary MD, Lacey JH, Bhat AV (1983) The neuroendocrine impact of 3-hydroxy-diazepam (temazepam) in women. Psychopharmacology 79: 295–297PubMedCrossRefGoogle Scholar
  4. Butler PWP, Besser GM, Steinberg H (1968) Changes in plasma Cortisol induced by dexamphetamine and chlordiazepoxide given alone and in combination in man. J Endocrinol 40: 391–392PubMedCrossRefGoogle Scholar
  5. Carlsson A (1978) Antipsychotic drugs, neurotransmitters and schizophrenia. Am J Psychiatry 135: 164–173Google Scholar
  6. Carlsson A (1988) The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1: 179–186PubMedCrossRefGoogle Scholar
  7. Carlsson, Lindqvist M (1963) Effect of chlorpromazine or haloperidol on formation of 3- methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol 20: 140–144CrossRefGoogle Scholar
  8. Charney DS, Menkes DB, Heninger GR (1981) Receptor sensitivity and the mechanism of action of antidepressant treatment. Implications for the etiology and therapy of depression. Arch Gen Psychiatry 38: 1160–1180Google Scholar
  9. Coppen A (1967) The biochemistry of affective disorders. Br J Psychiatry 113: 1237–1264PubMedCrossRefGoogle Scholar
  10. Costa E, Guidotti A, Toffano G (1978) Molecular mechanisms mediating the action of diazepam on GABA receptors. Br J Psychiatry 133: 239–248PubMedCrossRefGoogle Scholar
  11. Crawley JM, Hattox SE, Maas JN, Roth RH (1978) 3-methoxy-4-hydroxyphenetyleneglycol increase in plasma after stimulation of the nucleus locus coeruleus. Brain Res 141:380– 384Google Scholar
  12. Elam M, Yao T, Svensson TH, Thoren P (1984) Regulation of locus coeruleus neurons and splanchnic, sympathetic nerves by cardiovascular afferents. Brain Res 290: 281–287PubMedCrossRefGoogle Scholar
  13. Frantz AG, Kleinberg DL, Noel GL, Suh K (1972) Effects of neuroleptics on the secretion of prolactin and growth hormone. In: Ebling ETG, Henderson TW (eds) Endocrinology. Elsevier, New York, pp 144–149Google Scholar
  14. Gelato MC, PescovitzO, Cassoria F, Loriaux DL, Merriam GR (1984) Dose-response relationship for the effects of growth hormone-releasing factor (l-44)-NH2 in young adult men and women, J Clin Endocrinol Metab 59: 197–201Google Scholar
  15. Hyttel J (1982) Citalopram - pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity. Prog Neuropsychopharmacol Biol Psychiatry 6: 277–295PubMedCrossRefGoogle Scholar
  16. Koulu M, Lammintausta R, Kangas L, Dahlström S (1979) The effect of methysergide, pimozide, and sodium valproate on the diazepam-stimulated growth hormone secretion in man. J Clin Endocrinol Metab 48: 119–122PubMedCrossRefGoogle Scholar
  17. Laakmann G (1987) Psychopharmakologie und Depressionsforschung. Springer, Berlin Heidelberg New York TokyoGoogle Scholar
  18. Laakmann G, Schumacher G, Benkert O, von Werder K (1977) Stimulation of growth hormone secretion by desimipramin and chlorimipramin in man. J Clin Endocrinol Metab 44: 1010–1013PubMedCrossRefGoogle Scholar
  19. Laakmann G, Guillery T, Benkert O, Eversmann T (1979) Influence of nomifensine on growth hormone, prolactin, luteinising hormone and thyreotropin in healthy subjects and hyperprolactinaemic patients. In: Obiols J, Ballus C, Monclus EG, Pujol J (eds) Biological psychiatry today. Proceedings of the Und world conference on biological psychiatry 1978. Elsevier, Amsterdam, pp 705–710Google Scholar
  20. Laakmann G, Schön HW, Wittmann M (1981) Desipramine and growth hormone secretion. Lancet 11: 996CrossRefGoogle Scholar
  21. Laakmann G, Treusch J, Schmauß M, Schmitt E, Treusch U (1982 a) Comparison of growth hormone stimulation induced by desimipramine, diazepam and metaclazepam in man. Psychoneuroendocrinology 7:141 –146Google Scholar
  22. Laakmann G, Treusch J, Eichmeier A, Schmauß M, Treusch U, WahlsterU (1982 b) Inhibitory effect of phentolamine on diazepam-induced growth hormone secretion and lack of effect of diazepam on prolactin secretion in man. Psychoneuroendocrinology 7:135– 139Google Scholar
  23. Laakmann G, Wittmann M, Gugath M (1984) Effects of psychotropic drugs (desimipramine, chlorimipramine, sulpiride and diazepam) on the human HP A axis. Psychopharmacology 86: 66–70CrossRefGoogle Scholar
  24. Laakmann G, Schön HW, Blaschke D, Wittmann M (1985) Dose-dependent growth hormone, prolactin and Cortisol stimulation after i. v. administration of desimipramine in human subjects. Psychoneuroendocrinology 10: 83–93PubMedCrossRefGoogle Scholar
  25. Laakmann G, Zygan K, Schön HW, Weiss A, Wittmann M, Meissner R, Blaschke D ( 1986 a) Effects of receptor blockers (methysergide, propranolol, phentolamine, yohimbine and prazosin) on desimipramine-induced pituitary hormone stimulation in humans. I: Growth hormone. Psychoneuroendocrinology 11: 447–461Google Scholar
  26. Laakmann G, Schön HW, Zygan K, Weiss A, Wittmann M, Meissner R (1986b) Effects of receptor blockers (methysergide, propranolol, phentolamine, yohimbine and prazosin) on desimipramine-induced pituitary hormone stimulation in humans. II: Prolactin. Psychoneuroendocrinology 11: 465–474Google Scholar
  27. Laakmann G, Wittmann M, Schön HW, Zygan K, Weiss A, Meissner R, Müller OA, StallaGK ( 1986 c) Effects of receptor blockers (methysergide, propranolol, phentolamine, yohimbine and prazosin) on desimipramine-induced pituitary hormone stimulation in humans. Ill: Hypothalamo-pituitary-adrenocortical axis. Psychoneuroendocrinology 11: 475–489Google Scholar
  28. Lal S, Vega CE de la, Sourkes TL, Friesen HG (1973) Effect of apomorphine on growth hormone, prolactin, luteinizing hormone and follicle-stimulating hormone levels in human serum of normal men. J Clin Endocrinol Metab 37: 719–724Google Scholar
  29. Lal S, TolisG, Martin JB, Brown GM, Guyda H (1975) Effect of Clonidine on growth hormone, prolactin, luteinizing hormone, follicle-stimulating hormone and thyroid- stimulating hormone in the serum. J Clin Endocrinol Metab 41: 827–832Google Scholar
  30. Langer G, Sachar EJ, Gruen PH, Halpern FS (1977 a) Human prolactin responses to neuroleptic drugs correlate with antischizophrenic potency. Nature 266: 639–640Google Scholar
  31. Langer G, Sachar EJ, Halpern FS, Gruen PH, Solomon M ( 1977 b) The prolactin response to neuroleptic drugs. A test of dopaminergic blockade: Neuroendocrine studies in normal men. J Clin Endocrinol Metab 45: 996–1002Google Scholar
  32. Levin ER, Sharp B, Carlson HE (1984) Failure to confirm consistent stimulation of growth hormone by diazepam. Horm Res 19: 86–90PubMedCrossRefGoogle Scholar
  33. Lidbrink P, Jonsson G, Fuxe K (1971) The effect of imipramine-like drugs and antihistamine drugs on uptake mechanisms in the central noradrenaline and 5-hydroxytryptamine neurons. Neuropharmacology 10: 521–536PubMedCrossRefGoogle Scholar
  34. Martin JB, Reichlin S (1987) Clinical Neuroendocrinology. Davis, PhiladelphiaGoogle Scholar
  35. Möhler H, Okada T (1978) Biochemical identification of the site of action of benzodiazepines in human brain by 3 H-diazepam-binding. Life Sei 22: 985–996CrossRefGoogle Scholar
  36. Nair NPV, Lai S, Iskandar HI, Etienne P, Wood PL, Guyda H (1982) Effect of sulpiride, an atypical neuroleptic, on apomorphine-induced growth hormone secretion. Brain Res Bull 8: 857–891CrossRefGoogle Scholar
  37. Pozoedel, Lancranjan I (1978) Clinical use of drugs modifying the release of anterior pituitary hormones. In: Ganong WF, Martini L (eds) Frontiers in Neuroendocrinology, vol 5. Elsevier, New York, pp 207–247Google Scholar
  38. Rotrosen J, Angrist B, Geshin S, Paquin J, Branchey L, Oleshansky M, Halpern F, Sachar EJ (1979) Neuroendocrine effects of apomorphine: characterization of response pattern and application to schizophrenia research. Br J Psychiatr 135: 444–456CrossRefGoogle Scholar
  39. Schildkraut JJ (1965) The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 121: 509–522Google Scholar
  40. Squires RF, Braestrup (1977) Benzodiazepine receptors in rat brain. Nature 266: 732–734Google Scholar
  41. Starke K, Altmann KP (1973) Inhibition of adrenergic neurotransmission by Clonidine: An action on prejunctional a-receptors. Neuropharmacology 12: 339–347Google Scholar
  42. Syvälathi E, Kanto JH (1975) Serum growth hormone, serum immunoreactive insulin and blood glucose response to oral and intravenous diazepam in man. Int J Clin Pharmacol Biopharm 12: 74–82Google Scholar
  43. Waldmeier P, Baumann PA, Hauser K, Maitre L, Storni A (1982) Oxaprotiline, a noradrenaline uptake inhibitor with an active and inactive enantiomer. Biochem Pharmacol 31: 2169–2176PubMedCrossRefGoogle Scholar
  44. Wilson JD, King DJ, Sheridan B (1979) Tranquilizers and plasma prolactin. Br Med J 1:123 –124Google Scholar
  45. Wirz-Justice A, Pühringer W, Lacoste V, Graw P, Gastpar M (1976) Intravenous L-5- hydroxytryptophan in normal subjects: an interdisciplinary precursor loading study. Pharmacopsychiatria 9: 277–288CrossRefGoogle Scholar
  46. Wolfersdorf M, Wendt G, Binz U, Steiner B, Hole G (1988) CGP 12.103 A versus clomipramine in the treatment of depressed inpatients - results of a double-blind study. Pharmacopsychiatry 21: 203–207PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • G. Laakmann
  • A. Hinz
  • U. Voderholzer
  • R. Lehle
  • H. Neuhauser
  • M. Ortner
  • R. Meissner
    • 1
  1. 1.Psychiatrische KlinikUniversität MünchenMünchen 2Germany

Personalised recommendations